AZD0095

Cat. No.:	HY-148517
CAS No.:	2750001-23-9
Molecular Formula:	$C_{27}H_{32}N_8O_2$
Molecular Weight:	500.6
Target:	Monocarboxylate Transporter
Pathway:	Membrane Transporter/Ion Channel
Storage:	Powder -20°C 3 years In solvent -80°C 6 months -20°C 1 month



SOLVENT & SOLUBILITY

In Vitro

DMSO : 10 mg/mL (19.98 mM; Need ultrasonic)

Preparing Stock Solutions	Concentration \ Solvent \ Mass	1 mg	5 mg	10 mg
	1 mM	1.9976 mL	9.9880 mL	19.9760 mL
	5 mM	0.3995 mL	1.9976 mL	3.9952 mL
	10 mM	0.1998 mL	0.9988 mL	1.9976 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline
   Solubility: 1 mg/mL (2.00 mM); Suspended solution; Need ultrasonic
2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)
   Solubility: ≥ 1 mg/mL (2.00 mM); Clear solution
3. Add each solvent one by one: 10% DMSO >> 90% corn oil
   Solubility: ≥ 1 mg/mL (2.00 mM); Clear solution

BIOLOGICAL ACTIVITY

Description

AZD0095 is a selective and orally active MCT4 inhibitor (IC_{50}: 1.3 nM). AZD0095 effectively inhibits the tumor growth in NCI-H358 xenograft in combination with Cediranib (HY-10205)[1].

IC_{50} & Target

MCT4
1.3 nM (IC_{50})

In Vitro

AZD0095 (0-50 μM) inhibits cell proliferation in NCI-H358 cells (high expression of MCT4), with an IC_{50} of 26 nM[1].
MCE has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo	AZD0095 (100 mg/kg, p.o. bid) together with Cediranib (3 mg/kg, p.o.) reduces tumor growth in a murine NCI-H358 xenograft [1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Murine NCI-H358 xenograft[1]
Dosage:	100 mg/kg together with Cediranib (3 mg/kg)
Administration:	Oral administration (p.o.)
Result:	Reduced tumor growth more efficiently than AZD0095 or AZD2171 alone.

REFERENCES

[1]. Goldberg FW, et al. Discovery of Clinical Candidate AZD0095, a Selective Inhibitor of Monocarboxylate Transporter 4 (MCT4) for Oncology. J Med Chem. 2022 Dec 16.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA